Appia Bio
Pin Wang, PhD, is professor of chemical engineering and materials science, biomedical engineering, and pharmaceutical sciences and pharmacology, and a founding director of the Center for Immunoengineering at USC. Dr. Wang is an expert in targeted gene delivery, dendritic cell-directed cancer vaccines, and chimeric antigen receptor (CAR)-based cellular immunotherapy. He earned a PhD in chemical engineering from Caltech and a BS in macromolecular physics from the University of Science and Technology of China.
This person is not in the org chart
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).